Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 77% 0.23 [0.08-0.66] recov. time 8 (n) 262 (n) Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 62% 0.38 [0.18-0.82] no recov. 7/44 18/43 Tau​2 = 0.00; I​2 = 0.0% Early treatment 68% 0.32 [0.17-0.59] 7/52 18/305 68% improvement Goren 81% 0.19 [0.03-1.28] ICU 1/12 17/36 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 81% 0.19 [0.03-1.28] 1/12 17/36 81% improvement Montopoli 75% 0.25 [0.09-0.76] severe case Improvement, RR [CI] Treatment Control Bennani 95% 0.05 [0.00-2062] death 0/4 18/114 Lazzeri -23% 1.23 [0.81-1.87] death/ICU Tau​2 = 0.33; I​2 = 24.1% Prophylaxis 15% 0.85 [0.30-2.45] 0/4 18/114 15% improvement All studies 59% 0.41 [0.17-0.99] 8/68 53/455 59% improvement 6 antiandrogen COVID-19 studies c19early.com/aa Dec 5, 2021 Tau​2 = 0.64; I​2 = 70.2%; Z = 1.98 Effect extraction pre-specified Favors antiandrogen Favors control
Database of all antiandrogen COVID-19 studies. Submit updates/corrections.
 
Search:  
Restrict:    All    Early    Late    Prophylaxis
Jul 1
Animal Leach et al., Nature Communications, doi:10.1038/s41467-021-24342-y (Peer Reviewed)
animal study
The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
Details   In Vitro and animal study showing that the antiandrogen enzalutamide reduces TMPRSS2 levels in human lung cells and in mouse lungs.
Jun 5
Review Mauvais-Jarvis et al., Endocrinology, doi:10.1210/endocr/bqab114 (Review) (Peer Reviewed)
review
Do Anti-androgens Have Potential as Therapeutics for COVID-19?
Details   Review of research related to the potential benefits of anti-androgrens for COVID-19.
Feb 1
Early Cadegiani et al., Cureus, doi:10.7759/cureus.13047 (Peer Reviewed)
no recov., ↓62.0%, p=0.009
Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
Details   RCT 130 outpatients in Brazil, 54 treated with dutasteride, showing faster recovery with treatment. All patients received nitazoxanide. There were no hospitalizations, mechanical ventilation, or deaths. 34110420.2.0000.0008. Some percenta..
Nov 2
2020
PrEPPEP McCoy et al., Journal of the European Academy of Dermatology and Venereology, doi:10.1111/jdv.17021 (Peer Reviewed) 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia
Details   Retrospective 48 androgenetic alopecia patients in Brazil treated with dutasteride, compared with 48 propensity score matched androgenetic alopecia patients not taking any 5ARis, showing a statistically significant reduction in the freque..
Oct 6
2020
Early Cadegiani et al., medRxiv, doi:10.1101/2020.10.05.20206870 (Preprint)
recov. time, ↓76.7%, p=0.006
An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Details   Prospective study of 270 female COVID-19 patients in Brazil, 75 with hyperandrogenism, of which 8 were on spiralactone. Results suggest that HA patients may be at increased risk, and that spironolactone use may reduce the risk compared to..
Sep 25
2020
Late Goren et al., Journal of the European Academy of Dermatology and Venereology, doi:10.1111/jdv.16953 (Peer Reviewed)
ICU, ↓81.0%, p=0.08
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Details   Prospective study of 77 men hospitalized with COVID-19, 12 taking antiandrogens (9 dutasteride, 2 finasteride, 1 spironolactone), showing lower ICU admission with treatment (statistically significant with age-matched controls only when exc..
Sep 21
2020
PrEPPEP Lazzeri et al., medRxiv, doi:10.1101/2020.04.20.20068056 (Preprint)
death/ICU, ↑23.0%, p=0.33
Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy)
Details   Retrospective case-control study in Italy with 943 male COVID-19 patients, 45 on chronic 5ARI treatment (finasteride/dutasteride). There was significantly fewer COVID-19 patients >55 on 5ARI treatment compared to age-matched controls (5.5..
Aug 17
2020
PrEPPEP Bennani et al., Annals of Oncology, doi:10.1016/j.annonc.2020.08.2095 (Peer Reviewed)
death, ↓94.9%, p=1.00
Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy
Details   Retrospective 118 prostate cancer patients, 4 on androgren deprivation therapy, not showing significant differences (as expected with only 4 patients in the treatment group).
May 21
2020
N/A Wambier et al., Journal of the American Academy of Dermatology, doi:10.1016/j.jaad.2020.05.079 (Peer Reviewed) Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
Details   Analysis of 175 patients hospitalized with severe COVID-19, showing androgenetic alopecia (AGA) in 42% of women and 79% of men. Authors hypothesize that COVID-19 severity is androgen-mediated, and recommend study of antiandrogen treatments.
May 6
2020
PrEPPEP Montopoli et al., Annals of Oncology, doi:10.1016/j.annonc.2020.04.479 (Peer Reviewed)
severe case, ↓74.5%, p=0.01
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)
Details   Retrospective 5,273 prostate cancer patients on androgen-deprivation therapy (ADT), and 37,161 not on ADT, showing lower risk of cases with treatment.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit